Hepatic Steatosis Index Is Associated with Type I Diabetes Complications

被引:17
|
作者
Tripolino, Cesare [1 ]
Irace, Concetta [2 ]
Cutruzzola, Antonio [2 ]
Parise, Martina [1 ]
Barone, Milena [1 ]
Scicchitano, Caterina [1 ]
Cortese, Claudio [3 ]
Gnasso, Agostino [1 ]
机构
[1] Magna Graecia Univ Catanzaro, Dept Clin & Expt Med, Metab Dis Unit, Catanzaro, Italy
[2] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy
[3] Tor Vergata Univ, Dept Expt Med & Surg, Rome, Italy
来源
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY | 2019年 / 12卷
关键词
fatty liver; type; 1; diabetes; diabetes complications; FATTY LIVER-DISEASE; ADULT PATIENTS; PREVALENCE;
D O I
10.2147/DMSO.S221969
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of complications in type 1 diabetes (T1DM) patients. To date, several biochemical indexes of NAFLD have been developed. Among these, hepatic steatosis index (HSI) strongly relates with the results of magnetic resonance. Aim: The aim of the present study was to evaluate the possible association between HSI and complications in T1DM. Methods: Medical records of patients with T1DM were evaluated. Macro- and microvascular complications were evaluated by a combination of instrumental (ECG, carotid artery echo-Doppler, fundus examination, vibration threshold at biothesiometry) and laboratory examination. HSI was calculated based on gender, body mass index and transaminases level. Results: Of the 124 patients evaluated, 71 were free of complications and 53 had at least one complication. The prevalence of diabetes complications was: 27% for retinopathy, 15% for carotid atherosclerosis, 16% for neuropathy. HSI was directly correlated with age, disease duration, triglycerides, total daily insulin and inversely with HDL and eGFR. In logistic regression analysis, HSI was independently associated with diabetic complications. Conclusion: These findings show that HSI is independently associated with the presence of complications in subjects with T1DM. This can be of clinical utility, allowing a better diagnostic classification of the patient and possibly guiding the therapeutic choice.
引用
收藏
页码:2405 / 2410
页数:6
相关论文
共 50 条
  • [21] Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors
    Yu, Ming-Whei
    Lin, Chih-Lin
    Liu, Chun-Jen
    Huang, Yi-Wen
    Hu, Jui-Ting
    Wu, Wan-Jung
    Wu, Chih-Feng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2022, 121 (08) : 1478 - 1487
  • [22] Development and Validation of the Framingham Steatosis Index to Identify Persons With Hepatic Steatosis
    Long, Michelle T.
    Pedley, Alison
    Colantonio, Lisandro D.
    Massaro, Joseph M.
    Hoffmann, Udo
    Muntner, Paul
    Fox, Caroline S.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (08) : 1172 - +
  • [23] Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease
    Kjeldsen, Sasha A. S.
    Werge, Mikkel P.
    Grandt, Josephine
    Richter, Michael M.
    Thing, Mira
    Hetland, Liv E.
    Rashu, Elias B.
    Jensen, Anne-Sofie H.
    Winther-Sorensen, Marie
    Kellemann, Jesper Sloth
    Holst, Jens J.
    Junker, Anders E.
    Serizawa, Reza R.
    Vyberg, Mogens
    Gluud, Lise Lotte
    Albrechtsen, Nicolai J. Wewer
    AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2024, 327 (04): : G558 - G570
  • [24] Hepatic Steatosis Index and the Risk of Type 2 Diabetes Mellitus in China: Insights from a General Population-Based Cohort Study
    Cai, Xintian
    Gao, Jing
    Liu, Shasha
    Wang, Mengru
    Hu, Junli
    Hong, Jing
    Zhu, Qing
    Tuerxun, Guzailinuer
    Dang, Yujie
    Li, Nanfang
    DISEASE MARKERS, 2022, 2022
  • [25] Prevalence trends of type 2 diabetes treatment, dyslipidemia and hepatic steatosis in Northeast Germany
    Bashir, Aqsa
    Voelzke, Henry
    Henck, Vivien
    Schipf, Sabine
    Doerr, Marcus
    Nauck, Matthias
    Schmidt, Carsten Oliver
    Aghdassi, Ali
    Khattak, Muhammad N. K.
    Markus, Marcello R. P.
    Ittermann, Till
    JOURNAL OF PUBLIC HEALTH, 2024, 47 (01) : 24 - 33
  • [26] Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes
    Lingvay, Ildiko
    Raskin, Philip
    Szczepaniak, Lidia S.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2007, 21 (03) : 137 - 142
  • [27] Descriptive study of hepatic steatosis and associated morbidity in Primary Care. (ESTEATOAP Study)
    Cortes Rubio, J. A.
    Costa Zamora, P.
    Guerra Diaz, R.
    Candela Fernandez, M.
    Cortes Costa, M.
    MEDICINA DE FAMILIA-SEMERGEN, 2020, 46 (06): : 400 - 405
  • [28] Low-Grade Hepatic Steatosis Is Associated with Long-term Remission of Type 2 Diabetes Independent of Type of Bariatric-Metabolic Surgery
    Lautenbach, Anne
    Wernecke, Marie
    Mann, Oliver
    Wagner, Jonas
    Wolter, Stefan
    Stoll, Fabian
    Aberle, Jens
    OBESITY SURGERY, 2023, 33 (02) : 530 - 538
  • [29] Modified FIB-4 Index in Type 2 Diabetes Mellitus with Steatosis: A Non-Linear Predictive Model for Advanced Hepatic Fibrosis
    Kim, Jonghyun
    Ito, Takanori
    Arai, Taeang
    Atsukawa, Masanori
    Kawanaka, Miwa
    Toyoda, Hidenori
    Honda, Takashi
    Yu, Ming-Lung
    Yoon, Eileen L.
    Jun, Dae Won
    Cha, Kyungjoon
    Nguyen, Mindie H.
    DIAGNOSTICS, 2024, 14 (22)
  • [30] Hepatic Steatosis and Low Cardiorespiratory Fitness in Youth With Type 2 Diabetes
    Wittmeier, Kristy D. M.
    Wicklow, Brandy A.
    MacIntosh, Andrea C.
    Sellers, Elizabeth A. C.
    Ryner, Lawrence N.
    Serrai, Hacene
    Gardiner, Philip F.
    Dean, Heather J.
    McGavock, Jonathan M.
    OBESITY, 2012, 20 (05) : 1034 - 1040